The estimated Net Worth of David A Spellman is at least $744 Mille dollars as of 16 May 2023. Mr. Spellman owns over 63,567 units of Akebia Therapeutics stock worth over $642,936 and over the last 7 years he sold AKBA stock worth over $100,873. In addition, he makes $0 as Chief Financial Officer, Senior Vice President e Treasurer at Akebia Therapeutics.
Sign up
Mr. Spellman AKBA stock SEC Form 4 insiders trading
David has made over 5 trades of the Akebia Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 63,567 units of AKBA stock worth $68,017 on 16 May 2023.
The largest trade he's ever made was selling 63,567 units of Akebia Therapeutics stock on 16 May 2023 worth over $68,017. On average, David trades about 6,716 units every 60 days since 2018. As of 16 May 2023 he still owns at least 446,483 units of Akebia Therapeutics stock.
You can see the complete history of Mr. Spellman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Spellman biography
David A. Spellman has been appointed as Chief Financial Officer, Senior Vice President, Treasurer of the Company effective 6/29/2020. Since November 2019, Mr. Spellman has served as the Chief Financial Officer and Chief Business Officer of Intarcia Therapeutics, Inc., a biopharmaceutical company (“Intarcia”), where he oversees a wide range of company initiatives, including Business Development, Strategic Planning, Information Technology and the Project Management Office. Mr. Spellman previously served as the Chief Business Officer of Intarcia from June to November 2019. From March 2018 to June 2019, Mr. Spellman served as the Chief Financial Officer of Mersana Therapeutics, Inc., a clinical stage antibody drug conjugate company. From February 2006 to March 2018, Mr. Spellman served in a series of roles at Vertex Pharmaceuticals, Inc., a global biopharmaceutical company (“Vertex”), the most recent of which were Vice President, Corporate, Commercial and International Finance, from February 2017 to March 2018, and Vice President, International Finance and Accounting, from February 2015 to January 2017. While at Vertex, Mr. Spellman helped establish Vertex’s international headquarters, business operations and integrated finance teams in over a dozen countries, and he supported the global pricing, reimbursement and launches of Kalydeco® (ivacaftor) and Orkambi® (lumacaftor/ivacaftor), and the U.S. launch of INCIVEK (telaprevir). Prior to Vertex, Mr. Spellman spent four years at Millennium Pharmaceuticals, Inc., where he held several positions on the Finance team, including operating as a member of the VELCADE® (bortezomib) launch team. Mr. Spellman received a B.S. in economics from The Wharton School, University of Pennsylvania.
How old is David Spellman?
David Spellman is 44, he's been the Chief Financial Officer, Senior Vice President e Treasurer of Akebia Therapeutics since 2020. There are 17 older and 2 younger executives at Akebia Therapeutics. The oldest executive at Akebia Therapeutics Inc. is Adrian Adams, 69, who is the Independent Chairman of the Board.
What's David Spellman's mailing address?
David's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE, MA, 02142.
Insiders trading at Akebia Therapeutics
Over the last 11 years, insiders at Akebia Therapeutics have traded over $3,056,393 worth of Akebia Therapeutics stock and bought 2,141,907 units worth $27,915,834 . The most active insiders traders include Holdings A/S Novo, Muneer A Satter e Mark J Enyedy. On average, Akebia Therapeutics executives and independent directors trade stock every 28 days with the average trade being worth of $43,534. The most recent stock trade was executed by Nicole R. Hadas on 13 May 2024, trading 12,016 units of AKBA stock currently worth $15,140.
What does Akebia Therapeutics do?
akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.
What does Akebia Therapeutics's logo look like?
Complete history of Mr. Spellman stock trades at Akebia Therapeutics e Mersana Therapeutics Inc
Akebia Therapeutics executives and stock owners
Akebia Therapeutics executives and other stock owners filed with the SEC include:
-
John Butler,
President, Chief Executive Officer, Director -
Michel Dahan,
Chief Operating Officer, Senior Vice President -
Nicole Hadas,
Senior Vice President, Chief Legal Officer, Corporate Secretary -
Dell Faulkingham,
Senior Vice President, Chief Commercial Officer -
John P. Butler MBA,
CEO, Pres & Director -
Dr. Steven Keith Burke,
Sr. VP of R&D and Chief Medical Officer -
Dell Faulkingham,
Sr. VP & Chief Commercial Officer -
Michel Dahan,
Sr. VP & COO -
Jason A. Amello,
Exec. Officer -
Adrian Adams,
Independent Chairman of the Board -
Michael Rogers,
Independent Director -
Maxine Gowen,
Independent Director -
Michael Heffernan,
Independent Director -
Cynthia Smith,
Independent Director -
Mark Enyedy,
Independent Director -
Steven Gilman,
Independent Director -
Kristen Sheppard,
Vice President, Investor Relations -
Myles Wolf,
Independent Director -
Steven Burke,
Senior Vice President, Chief Medical Officer -
David Spellman,
Chief Financial Officer, Senior Vice President, Treasurer -
Douglas Jermasek M.B.A.,
VP of Marketing & Strategy -
Mercedes Carrasco,
Director of Corp. Communications -
Nicole R. Hadas,
Sr. VP, Chief Legal Officer & Sec. -
Violetta Cotreau,
Sr. VP, Chief Accounting Officer & Principal Accounting Officer -
Scott A Canute,
-
Duane Nash,
Director -
Ronald C Jr Renaud,
Director -
Muneer A Satter,
Director -
Michael D. Clayman,
Director -
Bradley Maroni,
SVP & Chief Medical Officer -
Anupam Dalal,
Director -
Michael S Wyzga,
Director -
Rita Jain,
SVP, Chief Medical Officer -
Karen L Tubridy,
SVP, Chief Development Officer -
Leanne M Zumwalt,
-
Ron Frieson,
-
Jodie Pope Morrison,
-
Robert Shalwitz,
Chief Medical Officer -
Bioventures Ltd Novartis,
10% owner -
Holdings A/S Novo,
10% owner -
Violetta Cotreau,
SVP, Chief Accounting Officer -
Jason Amello,
SVP, CFO & Treasurer -
Ellen Snow,
SVP, CFO and Treasurer -
Nicholas Grund,
Chief Commercial Officer -
Richard C Malabre,
Chief Accounting Officer -
Erik Ostrowski,
SVP, CFO, CBO & Treasurer